Prognostic Nutritional Index as a Biomarker in Metastatic Hormone‐Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization
PNI serves as a significant prognostic biomarker in mHSPC, correlating with overall survival and potentially influencing treatment efficacy between abiraterone acetate and enzalutamide. Integrating PNI into clinical practice may aid in tailoring individualized treatment options.
Authors
- Muhammet Bekir Hacıoğlu (ORCID: https://orcid.org/0000-0001-8490-3239)
- Funda Akkus
- Osman Köstek (ORCID: https://orcid.org/0000-0002-1901-5603)
- Orhun Akdoğan (ORCID: https://orcid.org/0000-0003-0212-1191)
- İlhan Hacıbekiroğlu (ORCID: https://orcid.org/0000-0002-0333-7405)
- Abdüssamet Çelebi (ORCID: https://orcid.org/0000-0002-6922-1018)
- İvo Gökmen (ORCID: https://orcid.org/0000-0002-0382-5396)
- Ahmet Küçükarda (ORCID: https://orcid.org/0000-0001-7399-2360)
- Murat Araz (ORCID: https://orcid.org/0000-0002-4632-9501)
- Ozan Yazıcı (ORCID: https://orcid.org/0000-0003-0038-3569)
- Fatma Akdag Kahvecioglu (ORCID: https://orcid.org/0000-0003-4656-0970)
- Bülent Erdoğan (ORCID: https://orcid.org/0000-0002-2158-3490)
- Ali Fuat Gürbüz (ORCID: https://orcid.org/0000-0003-1455-471X)
Institutions
- Sakarya University (TR)
- Trakya University (TR)
- Canakkale Onsekiz Mart Universitesi Tip Fakultesi Hastanesi (TR)
- Necmettin Erbakan University (TR)
- Marmara University (TR)
- Gazi University (TR)
Publication Details
- Journal
- The Prostate
- Published
- 2025-02-19
- DOI
- https://doi.org/10.1002/pros.24876
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 6.07